oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Use of subcutaneous and intravenous trastuzumab: real-world experience from three hospitals in Sweden
Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Oncology.
Breast Unit, Department of Surgery, Kalmar County Hospital, Kalmar, Sweden.
Department of Oncology, Sundsvall County Hospital, Sundsvall, Sweden.
Real World & Analytic Solutions (RWAS), IQVIA, Stockholm, Sweden.
Show others and affiliations
2019 (English)In: Future Oncology, ISSN 1479-6694, E-ISSN 1744-8301Article in journal (Refereed) Epub ahead of print
Abstract [en]

Aim: We aimed to describe the use of subcutaneous (sc.) trastuzumab use in a real-world setting.

Patients & methods: This retrospective cohort study evaluated electronic medical records of patients with early breast cancer and trastuzumab use from January 2010 to February 2018 in three hospitals in Sweden.

Results: In total, 363 patients received trastuzumab during study period. Of these, 217 (59.8%) patients started treatment with sc. trastuzumab and 146 (40.2%) with intravenous trastuzumab. After sc. trastuzumab approval, use of sc. trastuzumab increased from 70.2% in 2014 to 100% in 2017. Since 2013, 34 of 35 (97.4%) patients who started with intravenous trastuzumab switched to sc. formulation.

Conclusion: Trastuzumab sc. quickly became the prevailing formulation for treatment in HER2-positive early breast cancer.

Place, publisher, year, edition, pages
Future Medicine Ltd. , 2019.
Keywords [en]
HER2-positive, breast cancer, real-world setting, subcutaneous, trastuzumab
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-75589DOI: 10.2217/fon-2019-0160PubMedID: 31306041OAI: oai:DiVA.org:oru-75589DiVA, id: diva2:1343512
Available from: 2019-08-16 Created: 2019-08-16 Last updated: 2019-08-16Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Valachis, Antonis

Search in DiVA

By author/editor
Valachis, Antonis
By organisation
School of Medical SciencesÖrebro University Hospital
In the same journal
Future Oncology
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 9 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf